Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model

被引：0
|
作者：
Pascal Crépey
Louis Boiron
Rafael Rodrigo Araujo
Juan Guillermo Lopez
Audrey Petitjean
Expedito José de Albuquerque Luna
机构：
[1] University of Rennes,Department of Quantitative Methods in Public Health, UPRES
[2] Sanofi Pasteur,EA
[3] Sanofi Pasteur,7449 Reperes, EHESP
[4] Sanofi Pasteur,undefined
[5] Institute of Tropical Medicine (IMT) - University of São Paulo (USP),undefined
来源：
BMC Public Health | / 20卷
关键词：
QIV; Quadrivalent; Public health; Cost-effectiveness; Vaccine; Influenza; Brazil;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINATION IN GERMANY - LINKING A DYNAMIC TRANSMISSION MODEL WITH HEALTH AND ECONOMIC OUTCOMES
    Dolk, F. C.
    Eichner, M.
    Welte, R.
    Anastassopoulou, A.
    Van Bellinghen, L.
    Nautrup, Poulsen B.
    Van Vlaenderen, I
    Schmidt-Ott, R.
    Schwehm, M.
    Postma, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A339 - A339
  • [32] The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines
    Nichol, KL
    [J]. VACCINE, 2003, 21 (16) : 1769 - 1775
  • [33] Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy
    Mennini, Francesco Saverio
    Bini, Chiara
    Marcellusi, Andrea
    Rinaldi, Alessandro
    Franco, Elisabetta
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1867 - 1873
  • [34] Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program
    Zeevat, Florian
    Crepey, Pascal
    Dolk, F. Christiaan K.
    Postma, Arjan J.
    Breeveld-Dwarkasing, Vidya N. A.
    Postma, Maarten J.
    [J]. VALUE IN HEALTH, 2021, 24 (01) : 3 - 10
  • [35] COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINATION IN THE DUTCH NATIONAL INFLUENZA PREVENTION PROGRAM
    Zeevat, F.
    Crepey, P.
    Dolk, C.
    Postma, A. J.
    Breeveld-Dwarkasing, V. N. A.
    Postma, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S647 - S647
  • [36] Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines
    Weaver, M
    Krieger, J
    Castorina, J
    Walls, M
    Ciske, S
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (01) : 111 - 120
  • [37] Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States
    Clements, Karen M.
    Meier, Genevieve
    McGarry, Lisa J.
    Pruttivarasin, Narin
    Misurski, Derek A.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (05) : 1171 - 1180
  • [38] COST-EFFECTIVENESS ANALYSIS OF SWITCHING FROM A TRIVALENT TO A QUADRIVALENT INACTIVATED INFLUENZA VACCINE IN COLOMBIA
    Castro, R.
    Rueda, J. A.
    Drzewiecka, A.
    Gorecki, M.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S162 - S162
  • [39] Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
    Uruena, Analia
    Micone, Paula
    Magneres, Cecilia
    Mould-Quevedo, Joaquin
    Giglio, Norberto
    [J]. VACCINES, 2021, 9 (04)
  • [40] Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States
    de Boer, Pieter T.
    Crepey, Pascal
    Pitman, Richard J.
    Macabeo, Berengere
    Chit, Ayman
    Postma, Maarten J.
    [J]. VALUE IN HEALTH, 2016, 19 (08) : 964 - 975
12345